Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06473871 in hypertrophic skin scarring
NCT01730339Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2012
- Primary completion
- Oct 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of EXC 001 in Hypertrophic Scar (HS) (2 arms), sponsored by Pfizer. Primary endpoint: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) at Week 24. Started Dec 2012; status: completed.
02
Drugs
EXC 001
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT01730339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730339.